This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The investigators propose to carry out a study using gene transfer to treat the central nervous system (CNS) manifestations of late infantile neuronal ceroid lipofuscinoses (LINCL), a fatal, recessive disorder of the (CNS) in children.
The aim of this protocol is to study the genotype - phenotype correlations of the CNS manifestations of late infantile neuronal ceroid lipofuscinoses by: comparing the genotype to a neurologic assessment and LINCL clinical rating scale; magnetic resonance imaging (MRI) and magnetic resonance spectroscopic (MRS) assessments of the CNS; and routine clinical evaluations.The study will be carried out in children diagnosed with LINCL in all stages. The staging is based on a modification of the scale of Steinfeld et al. The study anticipates a total of 30 children assessed over a period of 18 months. Of these, the investigators anticipate that approximately two-thirds will not be entered into the proposed gene transfer protocol and thus approximately 20 will be available for this study to be reassessed at 1 year. The investigators anticipate that they will be able to capture a one-time genotype - phenotype snapshot for all 30, and a 1 year genotype - phenotype progression assessment for 20.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000047-47
Application #
7604165
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2007-04-01
Project End
2007-09-16
Budget Start
2007-04-01
Budget End
2007-09-16
Support Year
47
Fiscal Year
2007
Total Cost
$355
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
de Simone, Giovanni; Wang, Wenyu; Best, Lyle G et al. (2017) Target organ damage and incident type 2 diabetes mellitus: the Strong Heart Study. Cardiovasc Diabetol 16:64
Gerber, Linda M; Sievert, Lynnette L; Schwartz, Joseph E (2017) Hot flashes and midlife symptoms in relation to levels of salivary cortisol. Maturitas 96:26-32
De Marco, Marina; Gerdts, Eva; Mancusi, Costantino et al. (2017) Influence of Left Ventricular Stroke Volume on Incident Heart Failure in a Population With Preserved Ejection Fraction (from the Strong Heart Study). Am J Cardiol 119:1047-1052
Schachterle, William; Badwe, Chaitanya R; Palikuqi, Brisa et al. (2017) Sox17 drives functional engraftment of endothelium converted from non-vascular cells. Nat Commun 8:13963
Haring, Bernhard; Wang, Wenyu; Fretts, Amanda et al. (2017) Red meat consumption and cardiovascular target organ damage (from the Strong Heart Study). J Hypertens 35:1794-1800
Beheshtian, Azadeh; Shitole, Sanyog G; Segal, Alan Z et al. (2016) Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults. Atherosclerosis 253:47-53
Leung, Vivien; Chiu, Ya-Lin; Kotler, Donald P et al. (2016) Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation. HIV Clin Trials 17:55-62
de Simone, Giovanni; Roman, Mary J; De Marco, Marina et al. (2015) Hemodynamic Correlates of Abnormal Aortic Root Dimension in an Adult Population: The Strong Heart Study. J Am Heart Assoc 4:e002309
Bhatia, Rajeev; Lesser, Daniel J; Oliveira, Flavia G S A et al. (2015) Body Fat Composition: A Predictive Factor for Sleep Related Breathing Disorder in Obese Children. J Clin Sleep Med 11:1039-45
Ocean, Allyson J; Christos, Paul; Sparano, Joseph A et al. (2014) Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Invest New Drugs 32:542-8

Showing the most recent 10 out of 370 publications